VRTX logo

VERTEX PHARMACEUTICALS INC

VRTXNASDAQ
πŸ† #95 by market capEarnings Feb 10 Β· Post🧬Biotech
$515.02β–Ό $5.62 (βˆ’1.08%)
Market closed Β· at close
πŸ””
Track VRTX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$130.54B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
10.5%
Healthy
πŸ“ŠGross Margin
85.6%
High
πŸ’΅FCF Margin
24.7%
Strong
βš–οΈP/S Ratio
10.0x
Elevated
Otter Score
68
Fair
No chart data available for VRTX.

Trading Snapshot

Day Range
$513.87 – $531.37
52-Week Range
$412.27 – $568.67
Volume (shares)
1,767,923
Avg Volume (shares)
β€”
Shares Outstanding
253.5M
Next Earnings
2027-02-10

Fundamentals Snapshot

Annual Revenue
$12.07B
Last Q Revenue
$3.44B
P/E Ratio
32.6
P/S Ratio
10.0x
EPS (TTM)
$15.54
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.7%
VRTX logo

VERTEX PHARMACEUTICALS INC

VRTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12.1Bβ–² +9.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
85.0%β–Ό βˆ’1.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$4.8Bβ–Ό βˆ’2144.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3.2Bβ–Ό βˆ’504.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
256.1Mβ–Ό βˆ’1.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3.1Bβ–² +$234M YoY
StockOtter Β· stockotter.space

About VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
39 analysts
Strong Buy12
Buy20
Hold6
Sell0
Strong Sell1
Ratings as of Nov 2026

Latest News & Updates

Market WatchΒ·4d ago

Worried investors are paying up for these stocks β€” some with up to 49% upside, analysts say

Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.

The Motley FoolΒ·5d ago

Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expan

Seeking AlphaΒ·5d ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Defense WorldΒ·5d ago

5,362 Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banco Santander S.A.

Banco Santander S.A. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Seeking AlphaΒ·6d ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript

The Motley FoolΒ·9d ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain m